Literature DB >> 22451748

Mycobacterial infections in AIDS.

A R Hill1.   

Abstract

Tuberculosis (TB) remains uniquely important among acquired immune deficiency syndrome (AIDS)-associated opportunistic infections: it presents the greatest public health hazard worldwide, is the most readily curable, and is largely preventable with existing means. Given the expanding pool of human immunodeficiency virus (HIV) seropositive persons, particularly in developing nations where Mycobacterium tuberculosis remains a leading health problem, one can expect a continued rise in TB cases during the 1990s. Global efforts to eliminate TB are now inextricably entwined with the effectiveness of measures to curtail the HIV epidemic. Mycobacterium avium complex infection, currently an intractable late complication of aids, may increase in clinical importance as success in managing other opportunistic infections and HIV disease itself improves. Understanding of the pathogenesis and management of mycobacterial diseases should increase rapidly given the renewed research spurred on by the advent of HIV.

Entities:  

Keywords:  Acquired immune deficiency syndrome; Human immunodeficiency virus; Mycobacteria; Mycobacterium avium complex; Mycobacterium tuberculosis; Tuberculosis

Year:  1991        PMID: 22451748      PMCID: PMC3307397          DOI: 10.1155/1991/476503

Source DB:  PubMed          Journal:  Can J Infect Dis        ISSN: 1180-2332


  88 in total

1.  Disseminated infection with Mycobacterium kansasii in the acquired immunodeficiency syndrome.

Authors:  R Sherer; R Sable; M Sonnenberg; S Cooper; P Spencer; S Schwimmer; F Kocka; P Muthuswamy; C Kallick
Journal:  Ann Intern Med       Date:  1986-11       Impact factor: 25.391

2.  Mycobacterium avium complex infection in patients with the acquired immunodeficiency syndrome. A clinicopathologic study.

Authors:  J M Wallace; J B Hannah
Journal:  Chest       Date:  1988-05       Impact factor: 9.410

Review 3.  Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection.

Authors:  M S Meltzer; D R Skillman; P J Gomatos; D C Kalter; H E Gendelman
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

4.  DNA probes demonstrate a single highly conserved strain of Mycobacterium avium infecting AIDS patients.

Authors:  S J Hampson; F Portaels; J Thompson; E P Green; M T Moss; J Hermon-Taylor; J J McFadden
Journal:  Lancet       Date:  1989-01-14       Impact factor: 79.321

Review 5.  Effects of human immunodeficiency virus on pulmonary host defenses.

Authors:  J M Beck; J Shellito
Journal:  Semin Respir Infect       Date:  1989-06

6.  Fatal pericarditis due to Mycobacterium avium-intracellulare in acquired immunodeficiency syndrome.

Authors:  G L Woods; J C Goldsmith
Journal:  Chest       Date:  1989-06       Impact factor: 9.410

7.  Use of mycobacterial smears in the diagnosis of pulmonary tuberculosis in AIDS/ARC patients.

Authors:  N C Klein; F P Duncanson; T H Lenox; A Pitta; S C Cohen; G P Wormser
Journal:  Chest       Date:  1989-06       Impact factor: 9.410

8.  Characteristics of the acquired immunodeficiency syndrome (AIDS) in Haiti.

Authors:  J W Pape; B Liautaud; F Thomas; J R Mathurin; M M St Amand; M Boncy; V Pean; M Pamphile; A C Laroche; W D Johnson
Journal:  N Engl J Med       Date:  1983-10-20       Impact factor: 91.245

9.  Choosing an appropriate criterion for true or false conversion in serial tuberculin testing.

Authors:  P De March-Ayuela
Journal:  Am Rev Respir Dis       Date:  1990-04

10.  Evidence for heterosexual transmission and clinical manifestations of human immunodeficiency virus infection and related conditions in Lusaka, Zambia.

Authors:  M Melbye; E K Njelesani; A Bayley; K Mukelabai; J K Manuwele; F J Bowa; S A Clayden; A Levin; W A Blattner; R A Weiss
Journal:  Lancet       Date:  1986-11-15       Impact factor: 79.321

View more
  1 in total

Review 1.  Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases.

Authors:  Surendra K Sharma; Vishwanath Upadhyay
Journal:  Indian J Med Res       Date:  2020-09       Impact factor: 2.375

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.